February 24, 2022

COVID-19 vaccine, “COVIFENZ® ” (MT-2766)
has been approved in Canada.
Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; President &Representative Director: Hiroaki Ueno; hereinafter, “MTPC”) announced today thatits affiliated company, Medicago Inc. (Head Office: Quebec, Canada; President:Takashi Nagao) and GlaxoSmithKline plc (Head Office: London, UK, hereafter,“GSK”) jointly announced that Health Canada has granted full approval for

COVIFENZ® (COVID-19 vaccine, plant-based virus-like particles [VLP], projectcode: MT-2766) on February 24. COVIFENZ® is administered with GSKʼs pandemicadjuvant.
COVIFENZ® is a VLP vaccine indicated for the prevention of COVID-19, an infection
with the SARS-CoV-2 virus, in adults aged 18 to 64 years and is manufactured byusing plants. COVIFENZ® was reviewed under the rolling submission* in Canada
since last April and data from the Phase 3 part of the Phase 2/3 clinical study weresubmitted as the final part of the application dossier in last December. The resultsof the Phase 3 part showed efficacy against Delta and Gamma variants of 75.3%
and 88.6% respectively in an environment where variants were dominant during
the Phase 3 period. In addition, no related serious adverse events were observed.
Medicago has a contract with the Government of Canada to supply the purchased
doses of this vaccine. Medicago is committed to fulfilling this order as soon aspossible. In Japan, a Phase 1/2 clinical study has been ongoing since last October,and MTPC aims to apply for approval in the second quarter of fiscal 2022 by adding
the results of the clinical study in Japan to the data used for the application inCanada.
MTPC group positions vaccines as one of key R&D areas alongside the central
nervous system and immune-inflammation disease areas, and is also working todevelop new modalities of vaccines. MTPC Group will further contribute to theprevention of infectious diseases which is one of the worldʼs important social issue,
by delivering a new option of plant-based VLP vaccine as a novel type of vaccine.

1 / 2

*Rolling Submission (rolling submission, staged submission):
A system in which Health Canada reviews documents submitted in stages without
waiting for submission of all data in order to shorten the time from application toapproval.
Medicago release (February 24, 2022, local time)【Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an
Adjuvanted Plant-Based COVID-19 Vaccine】■About COVIFENZ®

COVIFENZ® uses a VLP expressing a spike protein of coronavirus and is used incombination with GSKʼs pandemic adjuvant. VLP vaccine 3.75μg and adjuvant will
be administered intramuscularly 2 times at 21-day intervals, and can be stored anddistributed in a refrigerator (2-8℃).

■About Medicago
Medicago is a Canadian biopharmaceutical company established in 1999 tospecialize in research and development of new vaccines using VLP technology. It
has a unique technology to extract and purify plants efficiently by generating VLP
in their cells through recombinant technology. Mitsubishi Tanabe Pharma iscommitted to creating new drugs that address unmet medical needs and building amanagement base to provide these products globally. Aiming to further develop thevaccine business through the acquisition of new biologics technologies, we becamea major shareholder in September 2013. We are currently engaged in thedevelopment of novel coronavirus and seasonal influenza vaccines, and throughresearch and development and manufacturing of various vaccines using VLP
technology, we are working to contribute to the health and prevention of infectious
diseases for people around the world.

Mitsubishi Tanabe Pharma Corporation
Communication Crossroads Department
Media contacts: TEL: +81 6 6205 5119

2 / 2